CALIDI BIOTHERAPEUTICS INC (CLDI)
US3207033099 - Common Stock
CLDI gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. CLDI has a bad profitability rating. Also its financial health evaluation is rather negative. CLDI is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year CLDI has reported negative net income.
CLDI had a negative operating cash flow in the past year.
1.2 Ratios
CLDI has a worse Return On Assets (-291.61%) than 94.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -291.61% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-531.04%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CLDI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CLDI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CLDI has been increased compared to 1 year ago.
CLDI has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -23.39, we must say that CLDI is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -23.39, CLDI is not doing good in the industry: 88.79% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -23.39 |
ROIC/WACCN/A
WACC9.93%
2.3 Liquidity
CLDI has a Current Ratio of 0.42. This is a bad value and indicates that CLDI is not financially healthy enough and could expect problems in meeting its short term obligations.
CLDI's Current ratio of 0.42 is on the low side compared to the rest of the industry. CLDI is outperformed by 94.31% of its industry peers.
A Quick Ratio of 0.42 indicates that CLDI may have some problems paying its short term obligations.
CLDI's Quick ratio of 0.42 is on the low side compared to the rest of the industry. CLDI is outperformed by 93.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.42 | ||
| Quick Ratio | 0.42 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 2.45% over the past year.
Looking at the last year, CLDI shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)2.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-486.95%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 24.90% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y71.64%
EPS Next 2Y39.12%
EPS Next 3Y24.9%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
CLDI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CLDI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CLDI's earnings are expected to grow with 24.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.12%
EPS Next 3Y24.9%
5. Dividend
5.1 Amount
No dividends for CLDI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CALIDI BIOTHERAPEUTICS INC
NYSEARCA:CLDI (12/20/2024, 8:04:02 PM)
Premarket: 1.38 +0.02 (+1.47%)1.36
-0.09 (-6.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners3.46%
Inst Owner Change103.92%
Ins Owners11.66%
Ins Owner Change6.91%
Market Cap23.83M
Analysts87.5
Price Target6.38 (369.12%)
Short Float %5.97%
Short Ratio0.48
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-55.15%
Min EPS beat(2)-129.55%
Max EPS beat(2)19.26%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-58.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)20.12%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.87
EYN/A
EPS(NY)-4.05
Fwd EYN/A
FCF(TTM)-1.57
FCFYN/A
OCF(TTM)-1.54
OCFYN/A
SpS0
BVpS-0.47
TBVpS-0.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -291.61% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-531.04%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 149.24% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.42 | ||
| Quick Ratio | 0.42 | ||
| Altman-Z | -23.39 |
F-Score3
WACC9.93%
ROIC/WACCN/A
Cap/Depr(3y)148.63%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-486.95%
EPS Next Y71.64%
EPS Next 2Y39.12%
EPS Next 3Y24.9%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-25.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-102.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-104.2%
OCF growth 3YN/A
OCF growth 5YN/A